This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Michel, R. B. Articles by Mattes, M. J. Search for Related Content PubMed PubMed Citation Articles by Michel, R. B. Articles by Mattes, M. J.

Antibody Localization to B-Cell Lymphoma Xenografts in Immunodeficient Mice: Importance of Using Residualizing Radiolabels¹

Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109

Antibody (Ab) localization to Raji B-cell lymphoma xenografts in severe combined immunodeficient (SCID) mice was investigated using three Abs: anti-CD20; anti-CD147; and anti-MHC class II. These antigens are all high-density cell surface antigens, and the Abs are all considered to be slowly internalized and catabolized, with catabolism primarily due to the basal turnover rate of cell surface constituents. Unexpectedly, specific Ab uptake was demonstrated only when residualizing labels were used. The residualizing labels tested were ¹¹¹In-benzyl-diethylenetriaminepentaacetic acid and [¹²⁵I]iodo-dilactitol-tyramine, whereas the nonresidualizing label was a conventional iodine label. In contrast, in vitro experiments demonstrated very slow catabolism of the same Abs. These data strongly suggest that Ab catabolism is much more rapid in vivo than in vitro and has a strong impact on Ab accumulation in the tumor. If autologous human tumors are similar to these xenografts, then there should be a large advantage in the use of residualizing radiolabels for radioimmunotherapy.

This article has been cited by other articles:

				R. M. Sharkey, H. Karacay, S. Litwin, E. A. Rossi, W. J. McBride, C.-H. Chang, and D. M. Goldenberg Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody Cancer Res., July 1, 2008; 68(13): 5282 - 5290. [Abstract] [Full Text] [PDF]

				R. M. Sharkey, H. Karacay, W. J. McBride, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg Bispecific Antibody Pretargeting of Radionuclides for Immuno Single-Photon Emission Computed Tomography and Immuno Positron Emission Tomography Molecular Imaging: An Update Clin. Cancer Res., September 15, 2007; 13(18): 5577s - 5585s. [Abstract] [Full Text] [PDF]

				R. B. Michel, P. M. Andrews, M. E. Castillo, and M. J. Mattes In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2 Mol. Cancer Ther., June 1, 2005; 4(6): 927 - 937. [Abstract] [Full Text] [PDF]

				R. B. Michel, A. V. Rosario, P. M. Andrews, D. M. Goldenberg, and M. J. Mattes Therapy of Small Subcutaneous B-Lymphoma Xenografts with Antibodies Conjugated to Radionuclides Emitting Low-Energy Electrons Clin. Cancer Res., January 15, 2005; 11(2): 777 - 786. [Abstract] [Full Text] [PDF]

				L. M. Rimsza, R. A. Roberts, T. P. Miller, J. M. Unger, M. LeBlanc, R. M. Braziel, D. D. Weisenberger, W. C. Chan, H. K. Muller-Hermelink, E. S. Jaffe, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project Blood, June 1, 2004; 103(11): 4251 - 4258. [Abstract] [Full Text] [PDF]

				R. Stein, S. V. Govindan, M. J. Mattes, S. Chen, L. Reed, G. Newsome, B. J. McBride, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg Improved Iodine Radiolabels for Monoclonal Antibody Therapy Cancer Res., January 1, 2003; 63(1): 111 - 118. [Abstract] [Full Text] [PDF]